|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
In the course of a prospective study of asymptomatic, multitransfused
subjects, seroconversion to human lymphadenopathy-associated virus
(LAV/HTLV-III) occurred in 34 hemophilic and in two thalassemic patients.
In subjects treated with procoagulant concentrates, primary infection, as
evidenced by the development of antibodies to LAV, was a clinically silent
event apart from moderate lymph node enlargement in 21% of cases.
Concomitant immunologic disturbances mainly affected T lymphocyte subsets.
This pattern contrasted with the major lymphadenopathy syndrome observed in
the thalassemic patients who received washed erythrocytes from single
donors positive for LAV antibodies. Four to 10 months after seroconversion,
the incidence of lymphadenopathy reached 46% and the immunologic profile
associated inverted T4+/T8+ lymphocyte ratio and markedly increased serum
levels of IgG. In multitransfused hemophiliac patients, primary infection
with LAV appears to provoke the following simplified sequence of events:
decrease of T4+ and increase of T8+ cell counts preceding or concomitant
with the occurrence of IgG LAV antibodies. Polyclonal elevation of IgG and
lymph node enlargement occur weeks or months later.
This article has been cited by other articles:
| |||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 1986 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
